SCHEMBL31240724

SCHEMBL31240724

FC(F)(F)Oc1cc(OCc2ccccc2)cc(-c2cc3c(-c4ccc5[nH]ncc5c4)ccnc3[nH]2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 2/20 0.49
▸ TRPA1 O75762 3/20 0.46
▸ SMO Q99835 1/20 0.43
▸ PRMT5 O14744 2/20 0.42
▸ METAP2 P50579 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ TRPM8 Q7Z2W7 1/20 0.40
▸ CCNT1 O60563 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ EGFR P00533 4/20 0.38
▸ MAPK14 Q16539 4/20 0.38
▸ CLK1 P49759 2/20 0.38
▸ CLK2 P49760 2/20 0.38
▸ DYRK1A Q13627 2/20 0.38
▸ CLK4 Q9HAZ1 2/20 0.38
▸ DYRK1B Q9Y463 2/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CLK3 P49761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240456 0.85 PRMT5 (0.46) CDC7PRMT5CCNT1CDK9EGFR
SCHEMBL31240802 0.79 PRMT5 (0.46) CDC7PRMT5CDK9
SCHEMBL31240677 0.79 PRMT5 (0.40) CDC7PRMT5CCNT1CDK9CLK2
SCHEMBL31240471 0.74 PRMT5 (0.48) CDC7PRMT5CDK9EGFRMAPK14
SCHEMBL31240648 0.72 TRPA1 (0.41) TRPA1TRPM8EGFRMAPK14CLK1
SCHEMBL31240574 0.71 CLK2 (0.51) PRMT5CLK2DYRK1ACDK2CLK3
SCHEMBL31240543 0.71 PRMT5 (0.61) PRMT5CLK2DYRK1ACLK3
SCHEMBL31240534 0.71 PRMT5 (0.51) CDC7PRMT5EGFRCLK2DYRK1A
SCHEMBL31240766 0.70 AURKA (0.47) TRPA1FGFR3CCNT1CDK9EGFR
SCHEMBL31240582 0.69 DYRK1A (0.49) CDC7PRMT5FGFR3CLK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
Send feedback